Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir for CMV Prophylaxis in Heart Transplant Recipients
NCT05432778Phase 2Recruiting
- Sponsor
- University Medical Centre Ljubljana
- Start
- May 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of letermovir in cytomegalovirus infection (CMV), sponsored by University Medical Centre Ljubljana. Primary endpoint: Rate of early CMV infections/disease during virostatic prophylaxis at 12 months. Started May 2023; status: recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05432778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432778.